Issue
Date Log
Copyright (c) 2026 Abdullah Mohammed Haef Alotaibi, Salman Abdulrahman Alotaibi, Muneera Abdulrhman Alotaibi, Mohammed Ahmed Darraj, Norah Mania Mutlag Alotaibi, Alaa Hayas Abdullah Alzahrani, Ahlam Omran Alsulami, Majed Shar Alshehri, Areej Saud Albalawi, Maram Saad Aljohani

This work is licensed under a Creative Commons Attribution 4.0 International License.
Maternal Cytomegalovirus Infection and Congenital Cytomegalovirus Disease: Laboratory Diagnosis, Antiviral Therapy, and Maternal–Pediatric Management
Corresponding Author(s) : Abdullah Mohammed Haef Alotaibi
Saudi Journal of Medicine and Public Health,
Vol. 3 No. 1 (2026)
Abstract
Background: Congenital cytomegalovirus (CMV) infection is the most common congenital viral infection and a major cause of sensorineural hearing loss and neurodevelopmental impairment in children. Maternal infection frequently remains undiagnosed because most women are asymptomatic or present with nonspecific manifestations.
Aim: This review examines the epidemiology, virology, pathogenesis, maternal risk factors, diagnostic approaches, preventive strategies, and clinical management of congenital CMV infection.
Methods: Relevant literature was reviewed to summarize current evidence on maternal primary and non-primary infections, viral latency, placental transmission, serological and molecular diagnosis, secondary prevention, neonatal assessment, antiviral treatment, and emerging vaccine strategies.
Results: Maternal primary and non-primary infections can result in fetal transmission, although the risk varies according to infection type and timing. Diagnosis remains challenging because of the limitations of maternal serological and molecular tests. Neonatal CMV PCR testing using urine or saliva collected within the first three weeks of life remains the diagnostic standard. High-dose valaciclovir may reduce fetal transmission following early maternal primary infection, while valganciclovir is recommended for selected symptomatic newborns, particularly those with central nervous system involvement. Long-term audiological and neurodevelopmental follow-up is necessary because complications may develop after birth, even in initially asymptomatic infants. Vaccine development remains challenging, and no licensed CMV vaccine is currently available.
Conclusion: Early maternal screening, accurate diagnosis, evidence-based preventive interventions, and appropriate neonatal management are essential to reduce the burden of congenital CMV infection. Further research should focus on improving diagnostic methods, understanding protective maternal immunity, and developing effective vaccines.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- 1. Zuhair, M.; Smit, G.S.A.; Wallis, G.; Jabbar, F.; Smith, C.; Devleesschauwer, B.; Griffiths, P. Estimation of the Worldwide Seroprevalence of Cytomegalovirus: A Systematic Review and Meta-Analysis. Rev. Med. Virol. 2019, 29, e2034.
- 2. Leruez-Ville, M.; Chatzakis, C.; Lilleri, D.; Blazquez-Gamero, D.; Alarcon, A.; Bourgon, N.; Foulon, I.; Fourgeaud, J.; Gonce, A.; Jones, C.E.; et al. Consensus Recommendation for Prenatal, Neonatal and Postnatal Management of Congenital Cytomegalovirus Infection from the European Congenital Infection Initiative (ECCI). Lancet Reg. Health-Eur. 2024, 40, 100892.
- 3. Liberati, C.; Sturniolo, G.; Brigadoi, G.; Cavinato, S.; Visentin, S.; Cosmi, E.; Donà, D.; Rampon, O. Burden of Congenital CMV Infection: A Narrative Review and Implications for Public Health Interventions. Viruses 2024, 16, 1311.
- 4. Tomtishen, J. Human Cytomegalovirus Tegument Proteins (Pp65, Pp71, Pp150, Pp28). Virol. J. 2012, 9, 22.
- 5. Poole, E.; Sinclair, J. Sleepless Latency of Human Cytomegalovirus. Med. Microbiol. Immunol. 2015, 204, 421–429.
- 6. Shahar-Nissan, K.; Oikawa Tepperberg, M.; Mendelson, E.; Bilavsky, E. Retrospective Identification of Congenital Cytomegalovirus Infection Using Dried Blood Samples—Missed Opportunities and Lessons. J. Clin. Virol. 2022, 152, 105186.
- 7. Leruez-Ville, M.; Foulon, I.; Pass, R.; Ville, Y. Cytomegalovirus Infection during Pregnancy: State of the Science. Am. J. Obstet. Gynecol. 2020, 223, 330–349.
- 8. Khalil, A.; Heath, P.; Jones, C.; Soe, A.; Ville, Y.; Royal College of Obstetricians and Gynaeocologists. Congenital Cytomegalovirus Infection: Update on Screening, Diagnosis and Treatment: Scientific Paper No. 56. BJOG 2025, 132, e42–e52.
- 9. Park, H.W.; Cho, M.H.; Bae, S.H.; Lee, R.; Kim, K.S. Incidence of Postnatal CMV Infection among Breastfed Preterm Infants: A Systematic Review and Meta-Analysis. J. Korean Med. Sci. 2021, 36, e84.
- 10. Leruez-Ville, M.; Magny, J.F.; Couderc, S.; Pichon, C.; Parodi, M.; Bussières, L.; Guilleminot, T.; Ghout, I.; Ville, Y. Risk Factors for Congenital Cytomegalovirus Infection Following Primary and Nonprimary Maternal Infection: A Prospective Neonatal Screening Study Using Polymerase Chain Reaction in Saliva. Clin. Infect. Dis. 2017, 65, 398–404.
- 11. Puhakka, L.; Lappalainen, M.; Lönnqvist, T.; Niemensivu, R.; Lindahl, P.; Nieminen, T.; Seuri, R.; Nupponen, I.; Pati, S.; Boppana, S.; et al. The Burden of Congenital Cytomegalovirus Infection: A Prospective Cohort Study of 20,000 Infants in Finland. J. Pediatr. Infect. Dis. Soc. 2019, 8, 205–212.
- 12. Mussi-Pinhata, M.M.; Yamamoto, A.Y.; Aragon, D.C.; Duarte, G.; Fowler, K.B.; Boppana, S.; Britt, W.J. Seroconversion for Cytomegalovirus Infection during Pregnancy and Fetal Infection in a Highly Seropositive Population: “The BraCHS Study”. J. Infect. Dis. 2018, 218, 1200–1204.
- 13. Fornara, C.; Zavaglio, F.; Furione, M.; Sarasini, A.; d’Angelo, P.; Arossa, A.; Spinillo, A.; Lilleri, D.; Baldanti, F. Human Cytomegalovirus (HCMV) Long-Term Shedding and HCMV-Specific Immune Response in Pregnant Women with Primary HCMV Infection. Med. Microbiol. Immunol. 2022, 211, 249–260.
- 14. Moskowitzova, K.; Naus, A.E.; Tsikis, S.T.; Dang, T.T.; Lin, S.B.; Zurakowski, D.; Fauza, D.O. Perinatal Vaccination by Transamniotic Fetal MRNA Delivery: Immunization Against Human Cytomegalovirus in a Rodent Model. J. Pediatr. Surg. 2025, 60, 161956.
- 15. Britt, W.J. Congenital Human Cytomegalovirus Infection and the Enigma of Maternal Immunity. J. Virol. 2017, 91, e02392-16.
- 16. Boppana, S.B.; Rivera, L.B.; Fowler, K.B.; Mach, M.; Britt, W.J. Intrauterine Transmission of Cytomegalovirus to Infants of Women with Preconceptional Immunity. N. Engl. J. Med. 2001, 344, 1366–1371.
- 17. Mussi-Pinhata, M.M.; Yamamoto, A.Y. Natural History of Congenital Cytomegalovirus Infection in Highly Seropositive Populations. J. Infect. Dis. 2021, 221, S15–S22.
- 18. Lazzarotto, T.; Gabrielli, L.; Lanari, M.; Guerra, B.; Bellucci, T.; Sassi, M.; Landini, M.P. Congenital Cytomegalovirus Infection: Recent Advances in the Diagnosis of Maternal Infection. Hum. Immunol. 2004, 65, 410–415.
- 19. Arora, N.; Sadovsky, Y.; Dermody, T.S.; Coyne, C.B. Microbial Vertical Transmission during Human Pregnancy. Cell Host Microbe 2017, 21, 561–567.
- 20. Auriti, C.; De Rose, D.U.; Santisi, A.; Martini, L.; Piersigilli, F.; Bersani, I.; Ronchetti, M.P.; Caforio, L. Pregnancy and Viral Infections: Mechanisms of Fetal Damage, Diagnosis and Prevention of Neonatal Adverse Outcomes from Cytomegalovirus to SARS-CoV-2 and Zika Virus. Biochim. Biophys. Acta Mol. Basis Dis. 2021, 1867, 166198.
- 21. Jensen, T.S.; Matre, R. Fc Gamma-Receptor Activity in the Developing Human Placenta. APMIS 1995, 103, 433–441.
- 22. Permar, S.R.; Schleiss, M.R.; Plotkin, S.A. Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections. J. Virol. 2018, 92, e00030-18.
- 23. Schleiss, M.R. Congenital Cytomegalovirus Infection: Improved Understanding of Maternal Immune Responses That Reduce the Risk of Transplacental Transmission. Clin. Infect. Dis. 2017, 65, 1666–1669.
- 24. Gerna, G.; Fornara, C.; Furione, M.; Lilleri, D. Congenital Human Cytomegalovirus Infection: A Narrative Review of Maternal Immune Response and Diagnosis in View of the Development of a Vaccine and Prevention of Primary and Non-Primary Infections in Pregnancy. Microorganisms 2021, 9, 1749.
- 25. Semmes, E.C.; Miller, I.G.; Wimberly, C.E.; Phan, C.T.; Jenks, J.A.; Harnois, M.J.; Berendam, S.J.; Webster, H.; Hurst, J.H.; Kurtzberg, J.; et al. Maternal Fc-Mediated Non-Neutralizing Antibody Responses Correlate with Protection against Congenital Human Cytomegalovirus Infection. J. Clin. Investig. 2022, 132, e156827.
- 26. Pereira, L.; Maidji, E.; McDonagh, S.; Genbacev, O.; Fisher, S. Human Cytomegalovirus Transmission from the Uterus to the Placenta Correlates with the Presence of Pathogenic Bacteria and Maternal Immunity. J. Virol. 2003, 77, 13301–13314.
- 27. Mcdonagh, S.; Maidji, E.; Ma, W.; Chang, H.-T.; Fisher, S.; Pereira, L. Viral and Bacterial Pathogens at the Maternal-Fetal Interface. J. Infect. Dis. 2004, 190, 826–834.
- 28. Maidji, E.; McDonagh, S.; Genbacev, O.; Tabata, T.; Pereira, L. Maternal Antibodies Enhance or Prevent Cytomegalovirus Infection in the Placenta by Neonatal Fc Receptor-Mediated Transcytosis. Am. J. Pathol. 2006, 168, 1210–1226.
- 29. Kagan, K.O.; Enders, M.; Schampera, M.S.; Baeumel, E.; Hoopmann, M.; Geipel, A.; Berg, C.; Goelz, R.; De Catte, L.; Wallwiener, D.; et al. Prevention of Maternal-Fetal Transmission of Cytomegalovirus after Primary Maternal Infection in the First Trimester by Biweekly Hyperimmunoglobulin Administration. Ultrasound Obstet. Gynecol. 2019, 53, 383–389.
- 30. Alfi, O.; Cohen, M.; Bar-On, S.; Hashimshony, T.; Levitt, L.; Raz, Y.; Blecher, Y.; Chaudhry, M.Z.; Cicin-Sain, L.; Ben-El, R.; et al. Decidual-Tissue-Resident Memory T Cells Protect against Nonprimary Human Cytomegalovirus Infection at the Maternal-Fetal Interface. Cell Rep. 2024, 43, 113698.
- 31. Uenaka, M.; Morizane, M.; Tanimura, K.; Deguchi, M.; Kanzawa, M.; Itoh, T.; Yamada, H. Histopathological Analysis of Placentas with Congenital Cytomegalovirus Infection. Placenta 2019, 75, 62–67.
- 32. Fisher, S.; Genbacev, O.; Maidji, E.; Pereira, L. Human Cytomegalovirus Infection of Placental Cytotrophoblasts In Vitro and In Utero: Implications for Transmission and Pathogenesis. J. Virol. 2000, 74, 6808–6820.
- 33. Pereira, L.; Petitt, M.; Tabata, T. Cytomegalovirus Infection and Antibody Protection of the Developing Placenta. Clin. Infect. Dis. 2013, 57, 174–177.
- 34. Preston, H.; Casey, R.; Ferris, E.; Kerr-Jones, L.; Jones, L.; Latif, F.; Clement, M.; Aicheler, R.J.; Wang, E.C.Y.; Stanton, R.J.; et al. Human Cytomegalovirus Immune Evasion of Natural Killer Cells: A Virus for All Seasons? Pathogens 2025, 14, 629.
- 35. Maidji, E.; Nigro, G.; Tabata, T.; McDonagh, S.; Nozawa, N.; Shiboski, S.; Muci, S.; Anceschi, M.M.; Aziz, N.; Adler, S.P.; et al. Antibody Treatment Promotes Compensation for Human Cytomegalovirus-Induced Pathogenesis and a Hypoxia-like Condition in Placentas with Congenital Infection. Am. J. Pathol. 2010, 177, 1298–1310.
- 36. Pontes, K.F.M.; Nardozza, L.M.M.; Peixoto, A.B.; Werner, H.; Tonni, G.; Granese, R.; Araujo Júnior, E. Cytomegalovirus and Pregnancy: A Narrative Review. J. Clin. Med. 2024, 13, 640.
- 37. Wreghitt, T.G.; Teare, E.L.; Sule, O.; Devi, R.; Rice, P. Cytomegalovirus Infection in Immunocompetent Patients. Clin. Infect. Dis. 2003, 37, 1603–1606.
- 38. Tanimura, K.; Tairaku, S.; Ebina, Y.; Morioka, I.; Nagamata, S.; Deguchi, K.; Morizane, M.; Deguchi, M.; Minematsu, T.; Yamada, H. Prediction of Congenital Cytomegalovirus Infection in High-Risk Pregnant Women. Clin. Infect. Dis. 2017, 64, 159–165.
- 39. Chatzakis, C.; Ville, Y.; Makrydimas, G.; Dinas, K.; Zavlanos, A.; Sotiriadis, A. Timing of Primary Maternal Cytomegalovirus Infection and Rates of Vertical Transmission and Fetal Consequences. Am. J. Obstet. Gynecol. 2020, 223, 870–883.e11.
- 40. Faure-Bardon, V.; Magny, J.F.; Parodi, M.; Couderc, S.; Garcia, P.; Maillotte, A.M.; Benard, M.; Pinquier, D.; Astruc, D.; Patural, H.; et al. Sequelae of Congenital Cytomegalovirus Following Maternal Primary Infections Are Limited to Those Acquired in the First Trimester of Pregnancy. Clin. Infect. Dis. 2019, 69, 1526–1532.
- 41. Chiereghin, A.; Pavia, C.; Gabrielli, L.; Piccirilli, G.; Squarzoni, D.; Turello, G.; Gibertoni, D.; Simonazzi, G.; Capretti, M.G.; Lanari, M.; et al. Clinical Evaluation of the New Roche Platform of Serological and Molecular Cytomegalovirus-Specific Assays in the Diagnosis and Prognosis of Congenital Cytomegalovirus Infection. J. Virol. Methods 2017, 248, 250–254.
- 42. Genco, F.; Sarasini, A.; Parea, M.; Prestia, M.; Scudeller, L.; Meroni, V. Comparison of the LIAISON ® XL and ARCHITECT IgG, IgM, and IgG Avidity Assays for the Diagnosis of Toxoplasma Gondii, Cytomegalovirus, and Rubella Virus Infections. New Microbiol. 2019, 42, 1121–7138.
- 43. Sarasini, A.; Arossa, A.; Zavattoni, M.; Fornara, C.; Lilleri, D.; Spinillo, A.; Baldanti, F.; Furione, M. Pitfalls in the Serological Diagnosis of Primary Human Cytomegalovirus Infection in Pregnancy Due to Different Kinetics of IgM Clearance and IgG Avidity Index Maturation. Diagnostics 2021, 11, 396.
- 44. Rawlinson, W.D.; Boppana, S.B.; Fowler, K.B.; Kimberlin, D.W.; Lazzarotto, T.; Alain, S.; Daly, K.; Doutré, S.; Gibson, L.; Giles, M.L.; et al. Congenital Cytomegalovirus Infection in Pregnancy and the Neonate: Consensus Recommendations for Prevention, Diagnosis, and Therapy. Lancet Infect. Dis. 2017, 17, e177–e188.
- 45. Maltezou, P.G.; Kourlaba, G.; Kourkouni, Ε.; Luck, S.; Blázquez-Gamero, D.; Ville, Y.; Lilleri, D.; Dimopoulou, D.; Karalexi, M.; Papaevangelou, V. Maternal Type of CMV Infection and Sequelae in Infants with Congenital CMV: Systematic Review and Meta-Analysis. J. Clin. Virol. 2020, 129, 104518.
- 46. Gatta, L.A.; Rochat, E.; Weber, J.M.; Valencia, S.; Erkanli, A.; Dotters-Katz, S.K.; Permar, S.; Hughes, B.L. Clinical Factors Associated with Cytomegalovirus Shedding among Seropositive Pregnant Women. Am. J. Obstet. Gynecol. MFM 2022, 4, 100560.
- 47. Nigro, G.; Adler, S.P.; La Torre, R.; Best, A.M.; Congenital Cytomegalovirus Collaborating group. Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection. N. Engl. J. Med. 2005, 353, 1350–1362.
- 48. Revello, M.G.; Lazzarotto, T.; Guerra, B.; Spinillo, A.; Ferrazzi, E.; Kustermann, A.; Guaschino, S.; Vergani, P.; Todros, T.; Frusca, T.; et al. A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus. N. Engl. J. Med. 2014, 370, 1316–1326.
- 49. Buxmann, H.; Stackelberg, O.M.; Rolf, L.S.; Enders, G.; Gonser, M.; Meyer-Wittkopf, M.; Hamprecht, K.; Enders, M.; Hamprecht, K. Use of Cytomegalovirus Hyperimmunoglobulin for Prevention of Congenital Cytomegalovirus Disease: A Retrospective Analysis. J. Perinat. Med. 2012, 40, 439–446.
- 50. Thürmann, P.A.; Sonnenburg-Chatzopoulos, C.; Lissner, R. Pharmacokinetic Characteristics and Tolerability of a Novel Intravenous Immunoglobulin Preparation. Eur. J. Clin. Pharmacol. 1995, 49, 237–242.
- 51. Hamprecht, K.; Bissinger, A.L.; Arellano-Galindo, J.; Schweinzer, K.; Jiang, X.; Göhring, K.; Mikeler, E.; Jahn, G. Intrafamilial Transmission of Human Cytomegalovirus (HCMV): Long-Term Dynamics of Epitope-Specific Antibody Response in Context of Avidity Maturation. J. Clin. Virol. 2014, 60, 119–126.
- 52. Hughes, B.L.; Clifton, R.G.; Rouse, D.J.; Saade, G.R.; Dinsmoor, M.J.; Reddy, U.M.; Pass, R.; Allard, D.; Mallett, G.; Fette, L.M.; et al. A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection. N. Engl. J. Med. 2021, 385, 436–444.
- 53. Nigro, G. Hyperimmune Globulin for Congenital Infection. N. Engl. J. Med. 2022, 386, 1001–1002.
- 54. Chatzakis, C.; Shahar-Nissan, K.; Faure-Bardon, V.; Picone, O.; Hadar, E.; Amir, J.; Egloff, C.; Vivanti, A.; Sotiriadis, A.; Leruez-Ville, M.; et al. The Effect of Valacyclovir on Secondary Prevention of Congenital Cytomegalovirus Infection, Following Primary Maternal Infection Acquired Periconceptionally or in the First Trimester of Pregnancy. An Individual Patient Data Meta-Analysis. Am. J. Obstet. Gynecol. 2024, 230, 109–117.e2.
- 55. Egloff, C.; Sibiude, J.; Vauloup-Fellous, C.; Benachi, A.; Bouthry, E.; Biquard, F.; Hawkins-Villarreal, A.; Houhou-Fidouh, N.; Mandelbrot, L.; Vivanti, A.J.; et al. New Data on Efficacy of Valacyclovir in Secondary Prevention of Maternal–Fetal Transmission of Cytomegalovirus. Ultrasound Obstet. Gynecol. 2023, 61, 59–66.
- 56. Faure-Bardon, V.; Fourgeaud, J.; Stirnemann, J.; Leruez-Ville, M.; Ville, Y. Secondary Prevention of Congenital Cytomegalovirus Infection with Valacyclovir Following Maternal Primary Infection in Early Pregnancy. Ultrasound Obstet. Gynecol. 2021, 58, 576–581.
- 57. Zammarchi, L.; Tomasoni, L.R.; Liuzzi, G.; Simonazzi, G.; Dionisi, C.; Mazzarelli, L.L.; Seidenari, A.; Maruotti, G.M.; Ornaghi, S.; Castelli, F.; et al. Treatment with Valacyclovir during Pregnancy for Prevention of Congenital Cytomegalovirus Infection: A Real-Life Multicenter Italian Observational Study. Am. J. Obstet. Gynecol. MFM 2023, 5, 101101.
- 58. Arcieri, F.; Vasta, A.; Sorrenti, S.; Volpe, G.; D’Ambrosio, V.; Di Mascio, D.; Natale, F.; Manganaro, L.; Liuzzi, G.; Corigliano, M.C.; et al. Antenatal Imaging and Neonatal Outcome in Infants with Congenital Cytomegalovirus Infection: The Effect of Valaciclovir. J. Clin. Med. 2026, 15, 809.
- 59. Jones, C.E.; Bailey, H.; Bamford, A.; Calvert, A.; Dorey, R.B.; Drysdale, S.B.; Khalil, A.; Heath, P.T.; Lyall, H.; Ralph, K.M.I.; et al. Managing Challenges in Congenital CMV: Current Thinking. Arch. Dis. Child. 2023, 108, 601–607.
- 60. Kenneson, A.; Cannon, M.J. Review and Meta-Analysis of the Epidemiology of Congenital Cytomegalovirus (CMV) Infection. Rev. Med. Virol. 2007, 17, 253–276.
- 61. Wang, L.; Xu, X.; Zhang, H.; Qian, J.; Zhu, J. Dried Blood Spots PCR Assays to Screen Congenital Cytomegalovirus Infection: A Meta-Analysis. Virol. J. 2015, 12, 60.
- 62. Bilavsky, E.; Watad, S.; Levy, I.; Linder, N.; Pardo, J.; Ben-Zvi, H.; Attias, J.; Amir, J. Positive IgM in Congenital CMV Infection. Clin. Pediatr. (Phila.) 2017, 56, 371–375.
- 63. Capretti, M.G.; Lanari, M.; Tani, G.; Ancora, G.; Sciutti, R.; Marsico, C.; Lazzarotto, T.; Gabrielli, L.; Guerra, B.; Corvaglia, L.; et al. Role of Cerebral Ultrasound and Magnetic Resonance Imaging in Newborns with Congenital Cytomegalovirus Infection. Brain Dev. 2014, 36, 203–211.
- 64. Giannattasio, A.; Bruzzese, D.; Di Costanzo, P.; Capone, E.; Romano, A.; D’Amico, A.; Bravaccio, C.; Grande, C.; Capasso, L.; Raimondi, F. Neuroimaging Profiles and Neurodevelopmental Outcome in Infants with Congenital Cytomegalovirus Infection. Pediatr. Infect. Dis. J. 2018, 37, 1028–1033.
- 65. Alarcón, A.; de Vries, L.S.; Parodi, A.; Arnáez, J.; Cabañas, F.; Steggerda, S.J.; Rebollo, M.; Ramenghi, L.; Dorronsoro, I.; López-Azorín, M.; et al. Neuroimaging in Infants with Congenital Cytomegalovirus Infection and Its Correlation with Outcome: Emphasis on White Matter Abnormalities. Arch. Dis. Child. Fetal Neonatal Ed. 2024, 109, 151–158.
- 66. Kimberlin, D.W.; Jester, P.M.; Sánchez, P.J.; Ahmed, A.; Arav-Boger, R.; Michaels, M.G.; Ashouri, N.; Englund, J.A.; Estrada, B.; Jacobs, R.F.; et al. Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease. N. Engl. J. Med. 2015, 372, 933–943.
- 67. Chung, P.K.; Schornagel, F.A.J.; Soede, W.; van Zwet, E.W.; Kroes, A.C.M.; Oudesluys-Murphy, A.M.; Vossen, A.C.T.M. Valganciclovir in Infants with Hearing Loss and Clinically Inapparent Congenital Cytomegalovirus Infection: A Nonrandomized Controlled Trial. J. Pediatr. 2024, 268, 113945.
- 68. Shang, Z.; Li, X. Human Cytomegalovirus: Pathogenesis, Prevention, and Treatment. Mol. Biomed. 2024, 5, 61.
- 69. Plotkin, S.A.; Boppana, S.B. Vaccination against the Human Cytomegalovirus. Vaccine 2019, 37, 7437–7442.
- 70. Ljungman, P.; Bermudez, A.; Logan, A.C.; Kharfan-Dabaja, M.A.; Chevallier, P.; Martino, R.; Wulf, G.; Selleslag, D.; Kakihana, K.; Langston, A.; et al. A Randomised, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ASP0113, a DNA-Based CMV Vaccine, in Seropositive Allogeneic Haematopoietic Cell Transplant Recipients. eClinicalMedicine 2021, 33, 100787.
- 71. Bancel, S. Reflecting on Moderna’s Phase 3 CMV Vaccine Readout. Available online: https://www.modernatx.com/media-center/all-media/blogs/phase-3-cmv-vaccine-readout-reflections
- 72. Lanzieri, T.M.; Bialek, S.R.; Ortega-Sanchez, I.R.; Gambhir, M. Modeling the Potential Impact of Vaccination on the Epidemiology of Congenital Cytomegalovirus Infection. Vaccine 2014, 32, 3780–3786.
- 73. Wang, C.; Zhang, X.; Bialek, S.; Cannon, M.J. Attribution of Congenital Cytomegalovirus Infection to Primary versus Non-Primary Maternal Infection. Clin. Infect. Dis. 2011, 52, e11–e13.
- 74. De Vries, J.J.C.; Van Zwet, E.W.; Dekker, F.W.; Kroes, A.C.M.; Verkerk, P.H.; Vossen, A.C.T.M. The Apparent Paradox of Maternal Seropositivity as a Risk Factor for Congenital Cytomegalovirus Infection: A Population-Based Prediction Model. Rev. Med. Virol. 2013, 23, 241–249.
References
1. Zuhair, M.; Smit, G.S.A.; Wallis, G.; Jabbar, F.; Smith, C.; Devleesschauwer, B.; Griffiths, P. Estimation of the Worldwide Seroprevalence of Cytomegalovirus: A Systematic Review and Meta-Analysis. Rev. Med. Virol. 2019, 29, e2034.
2. Leruez-Ville, M.; Chatzakis, C.; Lilleri, D.; Blazquez-Gamero, D.; Alarcon, A.; Bourgon, N.; Foulon, I.; Fourgeaud, J.; Gonce, A.; Jones, C.E.; et al. Consensus Recommendation for Prenatal, Neonatal and Postnatal Management of Congenital Cytomegalovirus Infection from the European Congenital Infection Initiative (ECCI). Lancet Reg. Health-Eur. 2024, 40, 100892.
3. Liberati, C.; Sturniolo, G.; Brigadoi, G.; Cavinato, S.; Visentin, S.; Cosmi, E.; Donà, D.; Rampon, O. Burden of Congenital CMV Infection: A Narrative Review and Implications for Public Health Interventions. Viruses 2024, 16, 1311.
4. Tomtishen, J. Human Cytomegalovirus Tegument Proteins (Pp65, Pp71, Pp150, Pp28). Virol. J. 2012, 9, 22.
5. Poole, E.; Sinclair, J. Sleepless Latency of Human Cytomegalovirus. Med. Microbiol. Immunol. 2015, 204, 421–429.
6. Shahar-Nissan, K.; Oikawa Tepperberg, M.; Mendelson, E.; Bilavsky, E. Retrospective Identification of Congenital Cytomegalovirus Infection Using Dried Blood Samples—Missed Opportunities and Lessons. J. Clin. Virol. 2022, 152, 105186.
7. Leruez-Ville, M.; Foulon, I.; Pass, R.; Ville, Y. Cytomegalovirus Infection during Pregnancy: State of the Science. Am. J. Obstet. Gynecol. 2020, 223, 330–349.
8. Khalil, A.; Heath, P.; Jones, C.; Soe, A.; Ville, Y.; Royal College of Obstetricians and Gynaeocologists. Congenital Cytomegalovirus Infection: Update on Screening, Diagnosis and Treatment: Scientific Paper No. 56. BJOG 2025, 132, e42–e52.
9. Park, H.W.; Cho, M.H.; Bae, S.H.; Lee, R.; Kim, K.S. Incidence of Postnatal CMV Infection among Breastfed Preterm Infants: A Systematic Review and Meta-Analysis. J. Korean Med. Sci. 2021, 36, e84.
10. Leruez-Ville, M.; Magny, J.F.; Couderc, S.; Pichon, C.; Parodi, M.; Bussières, L.; Guilleminot, T.; Ghout, I.; Ville, Y. Risk Factors for Congenital Cytomegalovirus Infection Following Primary and Nonprimary Maternal Infection: A Prospective Neonatal Screening Study Using Polymerase Chain Reaction in Saliva. Clin. Infect. Dis. 2017, 65, 398–404.
11. Puhakka, L.; Lappalainen, M.; Lönnqvist, T.; Niemensivu, R.; Lindahl, P.; Nieminen, T.; Seuri, R.; Nupponen, I.; Pati, S.; Boppana, S.; et al. The Burden of Congenital Cytomegalovirus Infection: A Prospective Cohort Study of 20,000 Infants in Finland. J. Pediatr. Infect. Dis. Soc. 2019, 8, 205–212.
12. Mussi-Pinhata, M.M.; Yamamoto, A.Y.; Aragon, D.C.; Duarte, G.; Fowler, K.B.; Boppana, S.; Britt, W.J. Seroconversion for Cytomegalovirus Infection during Pregnancy and Fetal Infection in a Highly Seropositive Population: “The BraCHS Study”. J. Infect. Dis. 2018, 218, 1200–1204.
13. Fornara, C.; Zavaglio, F.; Furione, M.; Sarasini, A.; d’Angelo, P.; Arossa, A.; Spinillo, A.; Lilleri, D.; Baldanti, F. Human Cytomegalovirus (HCMV) Long-Term Shedding and HCMV-Specific Immune Response in Pregnant Women with Primary HCMV Infection. Med. Microbiol. Immunol. 2022, 211, 249–260.
14. Moskowitzova, K.; Naus, A.E.; Tsikis, S.T.; Dang, T.T.; Lin, S.B.; Zurakowski, D.; Fauza, D.O. Perinatal Vaccination by Transamniotic Fetal MRNA Delivery: Immunization Against Human Cytomegalovirus in a Rodent Model. J. Pediatr. Surg. 2025, 60, 161956.
15. Britt, W.J. Congenital Human Cytomegalovirus Infection and the Enigma of Maternal Immunity. J. Virol. 2017, 91, e02392-16.
16. Boppana, S.B.; Rivera, L.B.; Fowler, K.B.; Mach, M.; Britt, W.J. Intrauterine Transmission of Cytomegalovirus to Infants of Women with Preconceptional Immunity. N. Engl. J. Med. 2001, 344, 1366–1371.
17. Mussi-Pinhata, M.M.; Yamamoto, A.Y. Natural History of Congenital Cytomegalovirus Infection in Highly Seropositive Populations. J. Infect. Dis. 2021, 221, S15–S22.
18. Lazzarotto, T.; Gabrielli, L.; Lanari, M.; Guerra, B.; Bellucci, T.; Sassi, M.; Landini, M.P. Congenital Cytomegalovirus Infection: Recent Advances in the Diagnosis of Maternal Infection. Hum. Immunol. 2004, 65, 410–415.
19. Arora, N.; Sadovsky, Y.; Dermody, T.S.; Coyne, C.B. Microbial Vertical Transmission during Human Pregnancy. Cell Host Microbe 2017, 21, 561–567.
20. Auriti, C.; De Rose, D.U.; Santisi, A.; Martini, L.; Piersigilli, F.; Bersani, I.; Ronchetti, M.P.; Caforio, L. Pregnancy and Viral Infections: Mechanisms of Fetal Damage, Diagnosis and Prevention of Neonatal Adverse Outcomes from Cytomegalovirus to SARS-CoV-2 and Zika Virus. Biochim. Biophys. Acta Mol. Basis Dis. 2021, 1867, 166198.
21. Jensen, T.S.; Matre, R. Fc Gamma-Receptor Activity in the Developing Human Placenta. APMIS 1995, 103, 433–441.
22. Permar, S.R.; Schleiss, M.R.; Plotkin, S.A. Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections. J. Virol. 2018, 92, e00030-18.
23. Schleiss, M.R. Congenital Cytomegalovirus Infection: Improved Understanding of Maternal Immune Responses That Reduce the Risk of Transplacental Transmission. Clin. Infect. Dis. 2017, 65, 1666–1669.
24. Gerna, G.; Fornara, C.; Furione, M.; Lilleri, D. Congenital Human Cytomegalovirus Infection: A Narrative Review of Maternal Immune Response and Diagnosis in View of the Development of a Vaccine and Prevention of Primary and Non-Primary Infections in Pregnancy. Microorganisms 2021, 9, 1749.
25. Semmes, E.C.; Miller, I.G.; Wimberly, C.E.; Phan, C.T.; Jenks, J.A.; Harnois, M.J.; Berendam, S.J.; Webster, H.; Hurst, J.H.; Kurtzberg, J.; et al. Maternal Fc-Mediated Non-Neutralizing Antibody Responses Correlate with Protection against Congenital Human Cytomegalovirus Infection. J. Clin. Investig. 2022, 132, e156827.
26. Pereira, L.; Maidji, E.; McDonagh, S.; Genbacev, O.; Fisher, S. Human Cytomegalovirus Transmission from the Uterus to the Placenta Correlates with the Presence of Pathogenic Bacteria and Maternal Immunity. J. Virol. 2003, 77, 13301–13314.
27. Mcdonagh, S.; Maidji, E.; Ma, W.; Chang, H.-T.; Fisher, S.; Pereira, L. Viral and Bacterial Pathogens at the Maternal-Fetal Interface. J. Infect. Dis. 2004, 190, 826–834.
28. Maidji, E.; McDonagh, S.; Genbacev, O.; Tabata, T.; Pereira, L. Maternal Antibodies Enhance or Prevent Cytomegalovirus Infection in the Placenta by Neonatal Fc Receptor-Mediated Transcytosis. Am. J. Pathol. 2006, 168, 1210–1226.
29. Kagan, K.O.; Enders, M.; Schampera, M.S.; Baeumel, E.; Hoopmann, M.; Geipel, A.; Berg, C.; Goelz, R.; De Catte, L.; Wallwiener, D.; et al. Prevention of Maternal-Fetal Transmission of Cytomegalovirus after Primary Maternal Infection in the First Trimester by Biweekly Hyperimmunoglobulin Administration. Ultrasound Obstet. Gynecol. 2019, 53, 383–389.
30. Alfi, O.; Cohen, M.; Bar-On, S.; Hashimshony, T.; Levitt, L.; Raz, Y.; Blecher, Y.; Chaudhry, M.Z.; Cicin-Sain, L.; Ben-El, R.; et al. Decidual-Tissue-Resident Memory T Cells Protect against Nonprimary Human Cytomegalovirus Infection at the Maternal-Fetal Interface. Cell Rep. 2024, 43, 113698.
31. Uenaka, M.; Morizane, M.; Tanimura, K.; Deguchi, M.; Kanzawa, M.; Itoh, T.; Yamada, H. Histopathological Analysis of Placentas with Congenital Cytomegalovirus Infection. Placenta 2019, 75, 62–67.
32. Fisher, S.; Genbacev, O.; Maidji, E.; Pereira, L. Human Cytomegalovirus Infection of Placental Cytotrophoblasts In Vitro and In Utero: Implications for Transmission and Pathogenesis. J. Virol. 2000, 74, 6808–6820.
33. Pereira, L.; Petitt, M.; Tabata, T. Cytomegalovirus Infection and Antibody Protection of the Developing Placenta. Clin. Infect. Dis. 2013, 57, 174–177.
34. Preston, H.; Casey, R.; Ferris, E.; Kerr-Jones, L.; Jones, L.; Latif, F.; Clement, M.; Aicheler, R.J.; Wang, E.C.Y.; Stanton, R.J.; et al. Human Cytomegalovirus Immune Evasion of Natural Killer Cells: A Virus for All Seasons? Pathogens 2025, 14, 629.
35. Maidji, E.; Nigro, G.; Tabata, T.; McDonagh, S.; Nozawa, N.; Shiboski, S.; Muci, S.; Anceschi, M.M.; Aziz, N.; Adler, S.P.; et al. Antibody Treatment Promotes Compensation for Human Cytomegalovirus-Induced Pathogenesis and a Hypoxia-like Condition in Placentas with Congenital Infection. Am. J. Pathol. 2010, 177, 1298–1310.
36. Pontes, K.F.M.; Nardozza, L.M.M.; Peixoto, A.B.; Werner, H.; Tonni, G.; Granese, R.; Araujo Júnior, E. Cytomegalovirus and Pregnancy: A Narrative Review. J. Clin. Med. 2024, 13, 640.
37. Wreghitt, T.G.; Teare, E.L.; Sule, O.; Devi, R.; Rice, P. Cytomegalovirus Infection in Immunocompetent Patients. Clin. Infect. Dis. 2003, 37, 1603–1606.
38. Tanimura, K.; Tairaku, S.; Ebina, Y.; Morioka, I.; Nagamata, S.; Deguchi, K.; Morizane, M.; Deguchi, M.; Minematsu, T.; Yamada, H. Prediction of Congenital Cytomegalovirus Infection in High-Risk Pregnant Women. Clin. Infect. Dis. 2017, 64, 159–165.
39. Chatzakis, C.; Ville, Y.; Makrydimas, G.; Dinas, K.; Zavlanos, A.; Sotiriadis, A. Timing of Primary Maternal Cytomegalovirus Infection and Rates of Vertical Transmission and Fetal Consequences. Am. J. Obstet. Gynecol. 2020, 223, 870–883.e11.
40. Faure-Bardon, V.; Magny, J.F.; Parodi, M.; Couderc, S.; Garcia, P.; Maillotte, A.M.; Benard, M.; Pinquier, D.; Astruc, D.; Patural, H.; et al. Sequelae of Congenital Cytomegalovirus Following Maternal Primary Infections Are Limited to Those Acquired in the First Trimester of Pregnancy. Clin. Infect. Dis. 2019, 69, 1526–1532.
41. Chiereghin, A.; Pavia, C.; Gabrielli, L.; Piccirilli, G.; Squarzoni, D.; Turello, G.; Gibertoni, D.; Simonazzi, G.; Capretti, M.G.; Lanari, M.; et al. Clinical Evaluation of the New Roche Platform of Serological and Molecular Cytomegalovirus-Specific Assays in the Diagnosis and Prognosis of Congenital Cytomegalovirus Infection. J. Virol. Methods 2017, 248, 250–254.
42. Genco, F.; Sarasini, A.; Parea, M.; Prestia, M.; Scudeller, L.; Meroni, V. Comparison of the LIAISON ® XL and ARCHITECT IgG, IgM, and IgG Avidity Assays for the Diagnosis of Toxoplasma Gondii, Cytomegalovirus, and Rubella Virus Infections. New Microbiol. 2019, 42, 1121–7138.
43. Sarasini, A.; Arossa, A.; Zavattoni, M.; Fornara, C.; Lilleri, D.; Spinillo, A.; Baldanti, F.; Furione, M. Pitfalls in the Serological Diagnosis of Primary Human Cytomegalovirus Infection in Pregnancy Due to Different Kinetics of IgM Clearance and IgG Avidity Index Maturation. Diagnostics 2021, 11, 396.
44. Rawlinson, W.D.; Boppana, S.B.; Fowler, K.B.; Kimberlin, D.W.; Lazzarotto, T.; Alain, S.; Daly, K.; Doutré, S.; Gibson, L.; Giles, M.L.; et al. Congenital Cytomegalovirus Infection in Pregnancy and the Neonate: Consensus Recommendations for Prevention, Diagnosis, and Therapy. Lancet Infect. Dis. 2017, 17, e177–e188.
45. Maltezou, P.G.; Kourlaba, G.; Kourkouni, Ε.; Luck, S.; Blázquez-Gamero, D.; Ville, Y.; Lilleri, D.; Dimopoulou, D.; Karalexi, M.; Papaevangelou, V. Maternal Type of CMV Infection and Sequelae in Infants with Congenital CMV: Systematic Review and Meta-Analysis. J. Clin. Virol. 2020, 129, 104518.
46. Gatta, L.A.; Rochat, E.; Weber, J.M.; Valencia, S.; Erkanli, A.; Dotters-Katz, S.K.; Permar, S.; Hughes, B.L. Clinical Factors Associated with Cytomegalovirus Shedding among Seropositive Pregnant Women. Am. J. Obstet. Gynecol. MFM 2022, 4, 100560.
47. Nigro, G.; Adler, S.P.; La Torre, R.; Best, A.M.; Congenital Cytomegalovirus Collaborating group. Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection. N. Engl. J. Med. 2005, 353, 1350–1362.
48. Revello, M.G.; Lazzarotto, T.; Guerra, B.; Spinillo, A.; Ferrazzi, E.; Kustermann, A.; Guaschino, S.; Vergani, P.; Todros, T.; Frusca, T.; et al. A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus. N. Engl. J. Med. 2014, 370, 1316–1326.
49. Buxmann, H.; Stackelberg, O.M.; Rolf, L.S.; Enders, G.; Gonser, M.; Meyer-Wittkopf, M.; Hamprecht, K.; Enders, M.; Hamprecht, K. Use of Cytomegalovirus Hyperimmunoglobulin for Prevention of Congenital Cytomegalovirus Disease: A Retrospective Analysis. J. Perinat. Med. 2012, 40, 439–446.
50. Thürmann, P.A.; Sonnenburg-Chatzopoulos, C.; Lissner, R. Pharmacokinetic Characteristics and Tolerability of a Novel Intravenous Immunoglobulin Preparation. Eur. J. Clin. Pharmacol. 1995, 49, 237–242.
51. Hamprecht, K.; Bissinger, A.L.; Arellano-Galindo, J.; Schweinzer, K.; Jiang, X.; Göhring, K.; Mikeler, E.; Jahn, G. Intrafamilial Transmission of Human Cytomegalovirus (HCMV): Long-Term Dynamics of Epitope-Specific Antibody Response in Context of Avidity Maturation. J. Clin. Virol. 2014, 60, 119–126.
52. Hughes, B.L.; Clifton, R.G.; Rouse, D.J.; Saade, G.R.; Dinsmoor, M.J.; Reddy, U.M.; Pass, R.; Allard, D.; Mallett, G.; Fette, L.M.; et al. A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection. N. Engl. J. Med. 2021, 385, 436–444.
53. Nigro, G. Hyperimmune Globulin for Congenital Infection. N. Engl. J. Med. 2022, 386, 1001–1002.
54. Chatzakis, C.; Shahar-Nissan, K.; Faure-Bardon, V.; Picone, O.; Hadar, E.; Amir, J.; Egloff, C.; Vivanti, A.; Sotiriadis, A.; Leruez-Ville, M.; et al. The Effect of Valacyclovir on Secondary Prevention of Congenital Cytomegalovirus Infection, Following Primary Maternal Infection Acquired Periconceptionally or in the First Trimester of Pregnancy. An Individual Patient Data Meta-Analysis. Am. J. Obstet. Gynecol. 2024, 230, 109–117.e2.
55. Egloff, C.; Sibiude, J.; Vauloup-Fellous, C.; Benachi, A.; Bouthry, E.; Biquard, F.; Hawkins-Villarreal, A.; Houhou-Fidouh, N.; Mandelbrot, L.; Vivanti, A.J.; et al. New Data on Efficacy of Valacyclovir in Secondary Prevention of Maternal–Fetal Transmission of Cytomegalovirus. Ultrasound Obstet. Gynecol. 2023, 61, 59–66.
56. Faure-Bardon, V.; Fourgeaud, J.; Stirnemann, J.; Leruez-Ville, M.; Ville, Y. Secondary Prevention of Congenital Cytomegalovirus Infection with Valacyclovir Following Maternal Primary Infection in Early Pregnancy. Ultrasound Obstet. Gynecol. 2021, 58, 576–581.
57. Zammarchi, L.; Tomasoni, L.R.; Liuzzi, G.; Simonazzi, G.; Dionisi, C.; Mazzarelli, L.L.; Seidenari, A.; Maruotti, G.M.; Ornaghi, S.; Castelli, F.; et al. Treatment with Valacyclovir during Pregnancy for Prevention of Congenital Cytomegalovirus Infection: A Real-Life Multicenter Italian Observational Study. Am. J. Obstet. Gynecol. MFM 2023, 5, 101101.
58. Arcieri, F.; Vasta, A.; Sorrenti, S.; Volpe, G.; D’Ambrosio, V.; Di Mascio, D.; Natale, F.; Manganaro, L.; Liuzzi, G.; Corigliano, M.C.; et al. Antenatal Imaging and Neonatal Outcome in Infants with Congenital Cytomegalovirus Infection: The Effect of Valaciclovir. J. Clin. Med. 2026, 15, 809.
59. Jones, C.E.; Bailey, H.; Bamford, A.; Calvert, A.; Dorey, R.B.; Drysdale, S.B.; Khalil, A.; Heath, P.T.; Lyall, H.; Ralph, K.M.I.; et al. Managing Challenges in Congenital CMV: Current Thinking. Arch. Dis. Child. 2023, 108, 601–607.
60. Kenneson, A.; Cannon, M.J. Review and Meta-Analysis of the Epidemiology of Congenital Cytomegalovirus (CMV) Infection. Rev. Med. Virol. 2007, 17, 253–276.
61. Wang, L.; Xu, X.; Zhang, H.; Qian, J.; Zhu, J. Dried Blood Spots PCR Assays to Screen Congenital Cytomegalovirus Infection: A Meta-Analysis. Virol. J. 2015, 12, 60.
62. Bilavsky, E.; Watad, S.; Levy, I.; Linder, N.; Pardo, J.; Ben-Zvi, H.; Attias, J.; Amir, J. Positive IgM in Congenital CMV Infection. Clin. Pediatr. (Phila.) 2017, 56, 371–375.
63. Capretti, M.G.; Lanari, M.; Tani, G.; Ancora, G.; Sciutti, R.; Marsico, C.; Lazzarotto, T.; Gabrielli, L.; Guerra, B.; Corvaglia, L.; et al. Role of Cerebral Ultrasound and Magnetic Resonance Imaging in Newborns with Congenital Cytomegalovirus Infection. Brain Dev. 2014, 36, 203–211.
64. Giannattasio, A.; Bruzzese, D.; Di Costanzo, P.; Capone, E.; Romano, A.; D’Amico, A.; Bravaccio, C.; Grande, C.; Capasso, L.; Raimondi, F. Neuroimaging Profiles and Neurodevelopmental Outcome in Infants with Congenital Cytomegalovirus Infection. Pediatr. Infect. Dis. J. 2018, 37, 1028–1033.
65. Alarcón, A.; de Vries, L.S.; Parodi, A.; Arnáez, J.; Cabañas, F.; Steggerda, S.J.; Rebollo, M.; Ramenghi, L.; Dorronsoro, I.; López-Azorín, M.; et al. Neuroimaging in Infants with Congenital Cytomegalovirus Infection and Its Correlation with Outcome: Emphasis on White Matter Abnormalities. Arch. Dis. Child. Fetal Neonatal Ed. 2024, 109, 151–158.
66. Kimberlin, D.W.; Jester, P.M.; Sánchez, P.J.; Ahmed, A.; Arav-Boger, R.; Michaels, M.G.; Ashouri, N.; Englund, J.A.; Estrada, B.; Jacobs, R.F.; et al. Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease. N. Engl. J. Med. 2015, 372, 933–943.
67. Chung, P.K.; Schornagel, F.A.J.; Soede, W.; van Zwet, E.W.; Kroes, A.C.M.; Oudesluys-Murphy, A.M.; Vossen, A.C.T.M. Valganciclovir in Infants with Hearing Loss and Clinically Inapparent Congenital Cytomegalovirus Infection: A Nonrandomized Controlled Trial. J. Pediatr. 2024, 268, 113945.
68. Shang, Z.; Li, X. Human Cytomegalovirus: Pathogenesis, Prevention, and Treatment. Mol. Biomed. 2024, 5, 61.
69. Plotkin, S.A.; Boppana, S.B. Vaccination against the Human Cytomegalovirus. Vaccine 2019, 37, 7437–7442.
70. Ljungman, P.; Bermudez, A.; Logan, A.C.; Kharfan-Dabaja, M.A.; Chevallier, P.; Martino, R.; Wulf, G.; Selleslag, D.; Kakihana, K.; Langston, A.; et al. A Randomised, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ASP0113, a DNA-Based CMV Vaccine, in Seropositive Allogeneic Haematopoietic Cell Transplant Recipients. eClinicalMedicine 2021, 33, 100787.
71. Bancel, S. Reflecting on Moderna’s Phase 3 CMV Vaccine Readout. Available online: https://www.modernatx.com/media-center/all-media/blogs/phase-3-cmv-vaccine-readout-reflections
72. Lanzieri, T.M.; Bialek, S.R.; Ortega-Sanchez, I.R.; Gambhir, M. Modeling the Potential Impact of Vaccination on the Epidemiology of Congenital Cytomegalovirus Infection. Vaccine 2014, 32, 3780–3786.
73. Wang, C.; Zhang, X.; Bialek, S.; Cannon, M.J. Attribution of Congenital Cytomegalovirus Infection to Primary versus Non-Primary Maternal Infection. Clin. Infect. Dis. 2011, 52, e11–e13.
74. De Vries, J.J.C.; Van Zwet, E.W.; Dekker, F.W.; Kroes, A.C.M.; Verkerk, P.H.; Vossen, A.C.T.M. The Apparent Paradox of Maternal Seropositivity as a Risk Factor for Congenital Cytomegalovirus Infection: A Population-Based Prediction Model. Rev. Med. Virol. 2013, 23, 241–249.